Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

The recommended phase II dose of paclitaxel 180 mg m(−2) given as a 3-h infusion followed by nedaplatin 100 mg m(−2) in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%....

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, I, Nokihara, H, Horiike, A, Yamamoto, N, Kunitoh, H, Ohe, Y, Tamura, T, Kodama, T, Saijo, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409664/
https://www.ncbi.nlm.nih.gov/pubmed/15026789
http://dx.doi.org/10.1038/sj.bjc.6601700
_version_ 1782155827004571648
author Sekine, I
Nokihara, H
Horiike, A
Yamamoto, N
Kunitoh, H
Ohe, Y
Tamura, T
Kodama, T
Saijo, N
author_facet Sekine, I
Nokihara, H
Horiike, A
Yamamoto, N
Kunitoh, H
Ohe, Y
Tamura, T
Kodama, T
Saijo, N
author_sort Sekine, I
collection PubMed
description The recommended phase II dose of paclitaxel 180 mg m(−2) given as a 3-h infusion followed by nedaplatin 100 mg m(−2) in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%.
format Text
id pubmed-2409664
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24096642009-09-10 Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma Sekine, I Nokihara, H Horiike, A Yamamoto, N Kunitoh, H Ohe, Y Tamura, T Kodama, T Saijo, N Br J Cancer Short Communication The recommended phase II dose of paclitaxel 180 mg m(−2) given as a 3-h infusion followed by nedaplatin 100 mg m(−2) in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%. Nature Publishing Group 2004-03-22 2004-03-02 /pmc/articles/PMC2409664/ /pubmed/15026789 http://dx.doi.org/10.1038/sj.bjc.6601700 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Sekine, I
Nokihara, H
Horiike, A
Yamamoto, N
Kunitoh, H
Ohe, Y
Tamura, T
Kodama, T
Saijo, N
Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title_full Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title_fullStr Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title_full_unstemmed Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title_short Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
title_sort phase i study of cisplatin analogue nedaplatin (254-s) and paclitaxel in patients with unresectable squamous cell carcinoma
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409664/
https://www.ncbi.nlm.nih.gov/pubmed/15026789
http://dx.doi.org/10.1038/sj.bjc.6601700
work_keys_str_mv AT sekinei phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT nokiharah phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT horiikea phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT yamamoton phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT kunitohh phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT ohey phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT tamurat phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT kodamat phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma
AT saijon phaseistudyofcisplatinanaloguenedaplatin254sandpaclitaxelinpatientswithunresectablesquamouscellcarcinoma

Ejemplares similares